You Position: Home > Paper

Current status and perspectives of bedaquiline in the treatment of multidrug/rifampicin-resistant tuberculosis

( views:0, downloads:0 )
Author:
No author available
Journal Title:
Chinese Journal of Tuberculosis and Respiratory Diseases
Issue:
3
DOI:
10.3760/cma.j.cn112147-20221129-00938
Key Word:
No keyword available

Abstract´╝Ü The prevalence of multidrug/rifampicin-resistant tuberculosis is still a major problem in China and around the world. Bedaquiline is one of the key drugs in the treatment of multidrug/rifampicin-resistant tuberculosis, with the potential to improve outcomes and reduce mortality. Bedaquiline has a promising future in oral short-course treatment regimens, in combination with other novel anti-tuberculosis drugs, and in a special patient population. In this feature article, we discussed the current status and future prospects of the clinical application of bedaquiline in order to provide references for physicians.

  • This article has no references!
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn